1/13
03:57 pm
bcab
BioAtla (NASDAQ:BCAB) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $4.00 price target on the stock.
Low
Report
BioAtla (NASDAQ:BCAB) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $4.00 price target on the stock.
1/2
04:54 am
bcab
BioAtla and GATC Health to advance Oz-V in Phase III trial [Yahoo! Finance]
High
Report
BioAtla and GATC Health to advance Oz-V in Phase III trial [Yahoo! Finance]
12/31
09:22 am
bcab
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) [Yahoo! Finance]
High
Report
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) [Yahoo! Finance]
12/31
07:00 am
bcab
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
High
Report
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
11/21
12:25 am
bcab
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
High
Report
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
11/14
07:08 pm
bcab
BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ... [Yahoo! Finance]
High
Report
BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ... [Yahoo! Finance]
11/13
06:54 pm
bcab
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch [Seeking Alpha]
High
Report
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch [Seeking Alpha]
11/13
06:52 pm
bcab
BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript [Seeking Alpha]
High
Report
BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript [Seeking Alpha]